{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-24-040655","form_type":"8-K","ticker":"HURA","cik":"0001498382","company_name":"TuHURA Biosciences, Inc./NV","filed_at":"2024-04-03T23:59:59+00:00","discovered_at":"2026-05-14T18:03:18.681319+00:00","generated_at":"2026-06-04T02:49:12.948100+00:00","sec_items":["1.01","5.02","7.01","8.01","9.01"],"event_type":"m_and_a","sentiment":"neutral","materiality_score":0.95,"calibrated_materiality_score":0.95,"confidence":"high","headline":"Kintara and TuHURA enter definitive merger; combined company to focus on immuno-oncology","bullets":["TuHURA stockholders to own ~97.15% of combined company; Kintara stockholders ~2.85% (or 94.55%/5.45% after CVR shares).","Combined company to trade as 'HURA' on Nasdaq; merger expected to close in Q3 2024.","TuHURA plans Phase 3 trial for IFx-2.0 personalized cancer vaccine in 2H 2024 under FDA accelerated approval pathway.","TuHURA has $31M subscribed financing of convertible notes to provide cash runway into late 2025.","CVRs issued to Kintara stockholders; up to 53.9M shares if milestone on REM-001 study met by Dec 31, 2025."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-24-040655","json":"https://secwatch.observer/filing/0000950170-24-040655.json","markdown":"https://secwatch.observer/filing/0000950170-24-040655.md","text":"https://secwatch.observer/filing/0000950170-24-040655.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1498382/000095017024040655/0000950170-24-040655-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1498382/000095017024040655/ktra-20240402.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-04T02:49:12.948100+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"3ee5ff1f53b82749f9786584beeecb1ce958697a","claim":"TuHURA Biosciences, Inc./NV entered into Agreement and Plan of Merger with Kintara Therapeutics, Inc., Kayak Mergeco, Inc. (effective 2024-04-02).","evidence_excerpt":"On April 2, 2024, Kintara Therapeutics, Inc. (“ Kintara ”), Kayak Mergeco, Inc., a wholly-owned subsidiary of Kintara incorporated in the State of Delaware (“ Merger Sub ”), and TuHURA Biosciences, Inc., a Delaware corporation (“ TuHURA ”), entered into an Agreement and Plan of Merger","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1498382/000095017024040655/0000950170-24-040655-index.htm","confidence":0.99,"family_label":"Material Agreements","details":[{"label":"Action","value":"entry"},{"label":"Agreement","value":"merger"},{"label":"Counterparty","value":"Kintara Therapeutics, Inc., Kayak Mergeco, Inc."},{"label":"Effective","value":"2024-04-02"}],"fact_type":"material_agreement"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}